This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2007 Sep;7(9):2062-3.

doi: 10.1111/j.1600-6143.2007.01925.x.

Valganciclovir versus IV ganciclovir for therapy of cytomegalovirus viremia: has victory been achieved?

PMID: 17697259
DOI: 10.1111/j.1600-6143.2007.01925.x

Free article

Editorial

Valganciclovir versus IV ganciclovir for therapy of cytomegalovirus viremia: has victory been achieved?

R K Avery. Am J Transplant. 2007 Sep.

Free article

. 2007 Sep;7(9):2062-3.

doi: 10.1111/j.1600-6143.2007.01925.x.

Author

PMID: 17697259
DOI: 10.1111/j.1600-6143.2007.01925.x

No abstract available

PubMed Disclaimer

Comment on

Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients.
Asberg A, Humar A, Rollag H, Jardine AG, Mouas H, Pescovitz MD, Sgarabotto D, Tuncer M, Noronha IL, Hartmann A; VICTOR Study Group. Asberg A, et al. Am J Transplant. 2007 Sep;7(9):2106-13. doi: 10.1111/j.1600-6143.2007.01910.x. Epub 2007 Jul 19. Am J Transplant. 2007. PMID: 17640310 Clinical Trial.

Similar articles

Preemptive valganciclovir for cytomegalovirus infection in hematological patients.
Focosi D, Benedetti E, Maggi F, Papineschi F, Galimberti S, Ceccherini-Nelli L, Petrini M. Focosi D, et al. Transpl Infect Dis. 2008 Oct;10(5):375-6. doi: 10.1111/j.1399-3062.2008.00306.x. Transpl Infect Dis. 2008. PMID: 18844864 No abstract available.
Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients.
Asberg A, Humar A, Jardine AG, Rollag H, Pescovitz MD, Mouas H, Bignamini A, Töz H, Dittmer I, Montejo M, Hartmann A; VICTOR Study Group. Asberg A, et al. Am J Transplant. 2009 May;9(5):1205-13. doi: 10.1111/j.1600-6143.2009.02617.x. Am J Transplant. 2009. PMID: 19422345 Clinical Trial.
Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts.
Razonable RR, Paya CV. Razonable RR, et al. Expert Rev Anti Infect Ther. 2004 Feb;2(1):27-41. doi: 10.1586/14787210.2.1.27. Expert Rev Anti Infect Ther. 2004. PMID: 15482169 Review.
Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients.
Wiltshire H, Paya CV, Pescovitz MD, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N, Zuideveld KP; Valganciclovir Solid Organ Transplant Study Group. Wiltshire H, et al. Transplantation. 2005 Jun 15;79(11):1477-83. doi: 10.1097/01.tp.0000164512.99703.ad. Transplantation. 2005. PMID: 15940035 Clinical Trial.
[Valganciclovir. Oral treatment of Cytomegalovirus infections].
Kroes AC. Kroes AC. Ned Tijdschr Geneeskd. 2004 Jun 19;148(25):1236-8. Ned Tijdschr Geneeskd. 2004. PMID: 15301386 Review. Dutch.

See all similar articles

Cited by

Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus.
Caldés A, Colom H, Armendariz Y, Garrido MJ, Troconiz IF, Gil-Vernet S, Lloberas N, Pou L, Peraire C, Grinyó JM. Caldés A, et al. Antimicrob Agents Chemother. 2009 Nov;53(11):4816-24. doi: 10.1128/AAC.00085-09. Epub 2009 Sep 8. Antimicrob Agents Chemother. 2009. PMID: 19738014 Free PMC article. Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Consumer Health Information
- MedlinePlus Health Information